Physician profile
Amit Borah
NPI 1770895179
$9,453.81
in general payments reported to CMS, 2019-2025
26 companies · $67.91 in 2025
The $67.91 reported for 2025 was less than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $935 · 2020: $652 · 2021: $31.99 · 2022: $171 · 2023: $2,128 · 2024: $5,468 · 2025: $67.91.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Education: $2,500 · Travel and Lodging: $2,433 · Consulting Fee: $1,400 · Food and Beverage: $1,321 · Gift: $8.74.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Education | $2,500.00 |
| Travel and Lodging | $2,433.29 |
| Consulting Fee | $1,400.00 |
| Food and Beverage | $1,320.93 |
| Gift | $8.74 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intuitive Surgical, INC. | $4,852.07 | 2024 | |
| Ethicon INC. | $1,954.28 | 2020-2023 | Monarch Platform |
| Veran Medical Technologies, INC. | $910.95 | 2019 | |
| Noah Medical Corporation | $644.80 | 2023 | |
| Pulmonx Corporation | $214.63 | 2022-2024 | Pulmonx Chartis Tablet Console, Zephyr Delivery Catheter, Zephyr Endobronchial Valve |
| La Jolla Pharmaceutical Company | $121.21 | 2022-2024 | Giapreza |
| Becton, Dickinson and Company | $102.00 | 2020 | |
| Jazz Pharmaceuticals INC. | $78.87 | 2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $62.24 | 2019-2024 | Ofev, Stiolto Respimat |
| Glaxosmithkline, LLC. | $56.96 | 2019-2024 | Trelegy Ellipta, Arexvy, Nucala |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $54.85 | 2024-2025 | Lifevest |
| Atricure, INC. | $53.68 | 2024 | |
| Lantheus Medical Imaging, INC. | $43.64 | 2023 | Definity |
| Regeneron Healthcare Solutions, INC. | $33.91 | 2024 | Dupixent |
| Philips North America LLC | $33.75 | 2024 | (Ak6) Vest Therapy |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abiomed | $33.06 | 2024 | Impella |
| Teleflex LLC | $32.63 | 2025 | Quikclot |
| Actelion Pharmaceuticals US, INC. | $31.91 | 2024 | Opsumit, Uptravi |
| Olympus America INC. | $28.00 | 2020 | |
| Bayer Healthcare Pharmaceuticals INC. | $20.86 | 2024 | |
| Takeda Pharmaceuticals U.S.A., INC. | $20.27 | 2024 | Aralast |
| Foundation Medicine, INC. | $15.78 | 2023 | Foundationone Cdx |
| Eclipse Technology Solutions INC. | $14.82 | 2024 | |
| Lilly USA, LLC | $13.07 | 2022 | |
| Sobi, INC | $12.85 | 2022 | |
| Amgen INC. | $12.72 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amit Borah listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.